Overview of current humman papilloma virus (HPV) vaccination Human Papilloma Virüs (HPV) Aşılamasına Güncel Bakış
TAF Preventive Medicine Bulletin, cilt.12, sa.3, ss.327-334, 2013 (Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 12 Sayı: 3
- Basım Tarihi: 2013
- Doi Numarası: 10.5455/pmb.1-1334292626
- Dergi Adı: TAF Preventive Medicine Bulletin
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.327-334
- Anahtar Kelimeler: Cervical Cancer, HPV, Vaccine
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Persistent viral infection with high-risk human papillomavirus (HPV) genotypes causes virtually all cancer of the cervix. The same HPV genotypes ("types") also cause cases of anal cancer. Cervical cancer is the third most frequent cancer in women worldwide after breast and colorectal cancers. It ranks fourth of women's cancers according to the mortality ratio. Two vaccines have been developed against HPV infection; one is a quadrivalent vaccine (Gardasil™) and the other is a bivalent vaccine (Cervarix™). This topic will cover issues related to HPV infections, routine HPV immunization recommendations, vaccination in special patient populations, the cost-effectiveness of HPV vaccination, and vaccine safety.